 Our indicative theme of Gene Editing stocks has returned about 11 year-to-date, compared to the SP 500 which is up by about 19 over the same period. However, the gains have overwhelmingly come from a single stock, Intellia Therapeutics, which is up by about 3x year-to-date, after the company. 